Supplemental Figure 8 shows ex vivo DBP profiling in AML PDX models guides generation of drug-resistant PDXs.
No takes yet. Share an insight, caveat, or question.
Olesinski et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: